SCHEMBL873141

SCHEMBL873141

NC1(OC(=O)O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11029381 0.97
SCHEMBL2827340 0.89 TSHR (0.32)
SCHEMBL2833245 0.89
SCHEMBL2831752 0.87 TSHR (0.36)
SCHEMBL2832088 0.87 TSHR (0.36)
SCHEMBL1840485 0.87 TSHR (0.36)
SCHEMBL4624265 0.83 KDM4E (0.36)
SCHEMBL6614400 0.82 ALDH1A1 (0.32)
SCHEMBL5674805 0.76
Hydrochloric Acid SCHEMBL16666609 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169403-B9 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-07-03 EP claimed
EP-3891176-B1 DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE HOLST BIRGITTE (DK) 2024-06-05 EP claimed
EP-3169403-B1 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-02-14 EP claimed
EP-3250191-B1 TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING NOVO NORDISK AS (DK) 2024-01-17 EP claimed
EP-2637698-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2022-04-20 EP claimed
EP-3600279-B1 1-AMINO-1-CYCLOPROPANECABOXYLIC ACID FORMULATIONS VALENT BIOSCIENCES LLC (US) 2022-03-09 EP claimed
EP-2932981-B1 Albumin-binding derivatives of GLP-1 NOVO NORDISK AS (DK) 2021-06-16 EP claimed
EP-3515191-B1 A METHOD FOR INCREASING ANTHOCYANIN CONTENT IN CARROTS UNIV COPENHAGEN (DK) 2021-03-17 EP claimed
EP-3225631-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2019-01-09 EP claimed
EP-2637699-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER NOVO NORDISK AS (DK) 2018-05-16 EP claimed
EP-0958305-B1 INHIBITIONS OF THE INTERACTION BETWEEN P53 AND MDM2 CANCER REC TECH LTD (GB) 2008-06-04 EP claimed
EP-0533832-B1 TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX US SECRETARY UNITED STATES DEP (US) 2002-11-20 EP claimed
EP-0528970-B1 METHODS AND COMPOSITIONS FOR MODULATING ETHYLENE LEVELS IN PLANT TISSUES CALGENE LLC (US) 1999-07-07 EP claimed
EP-0552417-B1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-07-07 EP claimed
EP-0920307-A2 DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM Roche Diagnostics GmbH (DE) 1999-06-09 EP claimed
EP-0767607-B1 USE OF COMPOUNDS WHICH INHIBIT EHTYLENE BIOSYNTHESIS IN HIGHER PLANTS FOR SOIL IMPROVEMENT BASF AG (DE) 1998-11-25 EP claimed
WO-1998006386-A2 DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM ROCHE DIAGNOSTICS GMBH (DE) 1998-02-19 WO claimed
EP-0528312-B1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-07-16 EP claimed
EP-0135429-B1 THE SYNTHESIS OF CYCLOPROPANE AMINO ACIDS AND PEPTIDES THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1992-03-18 EP claimed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP claimed